• Home
  • Search Results
  • Alzheimer's disease is not associated with altered concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid.

Alzheimer's disease is not associated with altered concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid.

Journal of neural transmission (Vienna, Austria : 1996) (2002-08-31)
C Mulder, L-O Wahlund, M Blomberg, S de Jong, G J van Kamp, P Scheltens, T Teerlink
ABSTRACT

Nitric oxide (NO) may play a role in the pathophysiology of Alzheimer's disease (AD). Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, is involved in regulation of NO production. Recently it has been reported that dimethylarginine dimethylaminohydrolase, an enzyme that hydrolyses ADMA into citrulline and dimethylamine, is specifically elevated in neurons displaying cytoskeletal abnormalities and oxidative stress in AD. We hypothesized that this could lead to altered CSF concentrations of ADMA in AD. Measurement of ADMA and dimethylamine in CSF revealed no significant differences between AD patients (n = 20) and age-matched control subjects (n = 20). Our results suggest that in early stages of AD overall regulation of NO production by ADMA is not aberrant.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Dimethylamine solution, 40 wt. % in H2O
Sigma-Aldrich
Dimethylamine, anhydrous, ≥99%
Sigma-Aldrich
Dimethylamine solution, 2.0 M in THF
Sigma-Aldrich
Dimethylamine solution, 2.0 M in methanol